Premium
MCI‐to‐normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative
Author(s) -
Thomas Kelsey R.,
Edmonds Emily C.,
Eppig Joel S.,
Wong Christina G.,
Weigand Alexandra J.,
Bangen Katherine J.,
Jak Amy J.,
DelanoWood Lisa,
Galasko Douglas R.,
Salmon David P.,
Edland Steven D.,
Bondi Mark W.
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.4948
Subject(s) - reversion , neuropsychology , dementia , biomarker , disease , neuroimaging , mean reversion , psychology , alzheimer's disease , demographics , medicine , cognition , psychiatry , demography , biology , biochemistry , sociology , gene , financial economics , economics , phenotype
The low mild cognitive impairment (MCI) to cognitively normal (CN) reversion rate in the Alzheimer's Disease Neuroimaging Initiative (2–3%) suggests the need to examine reversion by other means. We applied comprehensive neuropsychological criteria (NP criteria) to determine the resulting MCI to CN reversion rate. Methods Participants with CN (n = 641) or MCI (n = 569) were classified at baseline and year 1 using NP criteria. Demographic, neuropsychological, and Alzheimer's disease biomarker variables as well as progression to dementia were examined across stable CN, reversion, and stable MCI groups. Results NP criteria produced a one‐year reversion rate of 15.8%. Reverters had demographics, Alzheimer's disease biomarkers, and risk‐of‐progression most similar to the stable CN group and showed the most improvement on neuropsychological measures from baseline to year 1. Discussion NP criteria produced a reversion rate that is consistent with, albeit modestly improved from, reversion rates in meta‐analyses. Reverters' biomarker profiles and progression rates suggest that NP criteria accurately tracked with underlying pathophysiologic status.